Clinical Trial Update: Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Velcade (bortezomib) with melphalan in autologous stem-cell transplantation for multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Melphalan (Melphalan)
• Velcade (bortezomib)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED